The US has temporarily eased sanctions on Russian crude oil, suspending duties that could have reached 100% on major buyers, potentially increasing supply. However, oil supply risks have widened due to attacks on tankers and oil infrastructure in the Persian Gulf, Strait of Hormuz, and Red Sea, including missile interceptions and strikes on terminals. These conflicting factors create uncertainty in oil markets, with Brent and WTI prices showing cautious movements amid geopolitical tensions. Natural gas prices are bearish due to mild weather reducing demand despite lean supply. Market watchers will monitor if oil prices can sustain gains above key resistance levels or fall back amid ongoing risks.
Natural gas and oil market conditions provide context for this update, with 79 Energy-sector US stocks on Pluang showing mixed performance. As of Oct 19, 2026 13:11 WIB, 38 stocks rose while 37 fell. Notable movers include KGS at USD 47.21 with a 1-day change of -5.71%, NXE at USD 8.50 up 5.20%, and DNN at USD 2.27 up 5.09%, reflecting varied investor responses amid ongoing geopolitical tensions and supply concerns.
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
Red Cat Holdings announced a voluntary public purchase offer to acquire all outstanding shares of Steyr Motors AG at €39 per share in cash, representing a significant premium over recent prices. The acquisition aims to strengthen Red Cat's Blue Ops u...
Oculis Holding AG has completed patient randomization in its PREDICT-1 trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). The trial enrolled 176 patients, two-thirds carrying a genetic variant linked to b...
